ACB
Price
$3.92
Change
+$0.02 (+0.51%)
Updated
Oct 2, 04:59 PM (EDT)
Capitalization
258.5M
40 days until earnings call
Intraday BUY SELL Signals
CRON
Price
$3.22
Change
+$0.01 (+0.31%)
Updated
Oct 2, 04:59 PM (EDT)
Capitalization
1.26B
40 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ACB vs CRON

ACB vs CRON Comparison Chart in %
View a ticker or compare two or three
VS
ACB vs. CRON commentary
Oct 02, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACB is a Hold and CRON is a StrongBuy.

Interact to see
Advertisement
SUMMARIES
Loading...
FUNDAMENTALS RATINGS
ACB vs CRON: Fundamental Ratings
ACB
CRON
OUTLOOK RATING
1..100
8972
VALUATION
overvalued / fair valued / undervalued
1..100
49
Fair valued
47
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9680
PRICE GROWTH RATING
1..100
4441
P/E GROWTH RATING
1..100
8598
SEASONALITY SCORE
1..100
29n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CRON's Valuation (47) in the Pharmaceuticals Other industry is in the same range as ACB (49). This means that CRON’s stock grew similarly to ACB’s over the last 12 months.

CRON's Profit vs Risk Rating (100) in the Pharmaceuticals Other industry is in the same range as ACB (100). This means that CRON’s stock grew similarly to ACB’s over the last 12 months.

CRON's SMR Rating (80) in the Pharmaceuticals Other industry is in the same range as ACB (96). This means that CRON’s stock grew similarly to ACB’s over the last 12 months.

CRON's Price Growth Rating (41) in the Pharmaceuticals Other industry is in the same range as ACB (44). This means that CRON’s stock grew similarly to ACB’s over the last 12 months.

ACB's P/E Growth Rating (85) in the Pharmaceuticals Other industry is in the same range as CRON (98). This means that ACB’s stock grew similarly to CRON’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ACBCRON
RSI
ODDS (%)
Bearish Trend 2 days ago
76%
Bearish Trend 4 days ago
89%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
80%
Bearish Trend 2 days ago
86%
Momentum
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
84%
MACD
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
75%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
78%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
76%
Advances
ODDS (%)
Bullish Trend 11 days ago
76%
Bullish Trend 5 days ago
74%
Declines
ODDS (%)
Bearish Trend 3 days ago
84%
Bearish Trend 2 days ago
77%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
80%
Aroon
ODDS (%)
Bullish Trend 2 days ago
65%
Bullish Trend 2 days ago
87%
COMPARISON
Comparison
Oct 02, 2026
Stock price -- (ACB: $3.90 vs. CRON: $3.21)
Brand notoriety: ACB: Notable vs. CRON: Not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: ACB: 46% vs. CRON: 100%
Market capitalization -- ACB: $258.5M vs. CRON: $1.26B
ACB [@Pharmaceuticals: Generic] is valued at $258.5M. CRON’s [@Pharmaceuticals: Generic] market capitalization is $1.26B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $2.12K to $68.49B. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.13B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ACB’s FA Score shows that 0 FA rating(s) are green while CRON’s FA Score has 0 green FA rating(s).

  • ACB’s FA Score: 0 green, 5 red.
  • CRON’s FA Score: 0 green, 5 red.
According to our system of comparison, both ACB and CRON are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ACB’s TA Score shows that 5 TA indicator(s) are bullish while CRON’s TA Score has 2 bullish TA indicator(s).

  • ACB’s TA Score: 5 bullish, 4 bearish.
  • CRON’s TA Score: 2 bullish, 6 bearish.
According to our system of comparison, ACB is a better buy in the short-term than CRON.

Price Growth

ACB (@Pharmaceuticals: Generic) experienced а -6.25% price change this week, while CRON (@Pharmaceuticals: Generic) price change was -3.31% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -4.71%. For the same industry, the average monthly price growth was -8.12%, and the average quarterly price growth was +29.84%.

Reported Earning Dates

ACB is expected to report earnings on Nov 11, 2026.

CRON is expected to report earnings on Nov 11, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (-4.71% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

View a ticker or compare two or three
ACB
Daily Signal:
Gain/Loss:
CRON
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
ABLG30.350.09
+0.31%
Abacus FCF International Leaders ETF (ABLG)
METV20.940.03
+0.14%
Roundhill Ball Metaverse ETF (METV)
KOKU133.41N/A
N/A
Xtrackers MSCI Kokusai Equity ETF (KOKU)
SPEM51.50-0.26
-0.50%
State Street SPDR Portfolio Emerging Markets ETF (SPEM)
IJUN31.06-0.17
-0.54%
Innovator International Developed Power Buffer ETF - June (IJUN)

ACB and

Correlation & Price change

A.I.dvisor indicates that over the last year, ACB has been closely correlated with TLRY. These tickers have moved in lockstep 73% of the time. This A.I.-generated data suggests there is a high statistical probability that if ACB jumps, then TLRY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ACB
1D Price
Change %
ACB100%
N/A
TLRY - ACB
73%
Closely correlated
-4.80%
CGC - ACB
73%
Closely correlated
-1.54%
OGI - ACB
69%
Closely correlated
-1.37%
CRON - ACB
67%
Closely correlated
-2.73%
SNDL - ACB
65%
Loosely correlated
-2.33%
More